CareDx, Inc. - Common Stock (CDNA)

87.41
+15.89 (22.22%)
NASDAQ · Last Trade: Oct 31st, 11:59 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close71.52
Open80.61
Bid87.40
Ask88.00
Day's Range80.44 - 90.87
52 Week Range14.27 - 90.87
Volume3,554,614
Market Cap4.60B
PE Ratio (TTM)36.57
EPS (TTM)2.4
Dividend & YieldN/A (N/A)
1 Month Average Volume1,456,841

Chart

About CareDx, Inc. - Common Stock (CDNA)

CareDx Inc is a leading company in the field of precision medicine, specializing in organ transplant diagnostics. The company focuses on improving the lives of transplant patients through innovative testing solutions that help monitor and manage the risk of transplant rejection. By leveraging advanced genomic technologies, CareDx develops and commercializes a range of products, including non-invasive tests that analyze the patient's blood to provide critical information about organ health. Their commitment to enhancing patient care and outcomes has established them as a key player in the transplant community. Read More

News & Press Releases

Why CareDx Stock Soared Todayfool.com
The precision medicine pioneer is helping to improve patient care.
Via The Motley Fool · October 30, 2026
Gap-Up and Gap-Down Stocks for October 30, 2026chartmill.com
Via Chartmill · October 30, 2026
CareDx (CDNA) Q3 2026 Earnings Call Transcriptfool.com
Testing volumes surged 51% as NavDx integration drove revenue and margin gains.
Via The Motley Fool · October 30, 2026
What CareDx (CDNA) Said on Its Q3 Earnings Callmarketbeat.com
CareDx (NASDAQ:CDNA) reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July acquisition of Naveris. Revenue for the quarter ended Sept. 30 was $139 million, up 39% from a yea
Via MarketBeat · October 29, 2026
CareDx (NASDAQ:CDNA): Strong Growth Meets Technical Setup Qualitychartmill.com
Via Chartmill · October 27, 2026
CareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving Fundamentalschartmill.com
Via Chartmill · October 12, 2026
CAREDX INC (NASDAQ:CDNA): High Growth and Improving Fundamentals Fuel Bullish Casechartmill.com
Via Chartmill · September 19, 2026
After-Hours Market Movers: Oct. 29, 2026 Gainers and Loserschartmill.com
Via Chartmill · October 29, 2026
CareDx Announces Third Quarter 2026 Financial Results
CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026.
By CareDx, Inc. · Via Business Wire · October 29, 2026
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) being presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 22–25 in Denver, Colorado.
By CareDx, Inc. · Via Business Wire · October 22, 2026
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after market close on Thursday, October 29, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.
By CareDx, Inc. · Via Business Wire · October 15, 2026
CareDx (NASDAQ:CDNA) Meets Minervini Trend Template with High-Growth Momentumchartmill.com
Via Chartmill · September 10, 2026
CareDx (NASDAQ:CDNA) Screens Well on High Growth Momentum and Breakout Setupchartmill.com
Via Chartmill · September 5, 2026
CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screenchartmill.com
Via Chartmill · August 28, 2026
CareDx (NASDAQ:CDNA) Combines Strong Growth With a Bullish Technical Setupchartmill.com
Via Chartmill · August 25, 2026
CareDx (NASDAQ:CDNA) Passes Minervini Trend Template and High Growth Momentum Screenchartmill.com
Via Chartmill · August 19, 2026
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants.
By CareDx, Inc. · Via Business Wire · August 7, 2026
CareDx (NASDAQ:CDNA) Posts Accelerating Growth and Strengthening Fundamentalschartmill.com
Via Chartmill · August 6, 2026
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company’s newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally’s employment with CareDx.
By CareDx, Inc. · Via Business Wire · July 31, 2026
Why CareDx Stock Jumped Todayfool.com
The diagnostics leader is accelerating the trend toward precision medicine.
Via The Motley Fool · July 31, 2026
CareDx Q2 Earnings Call Highlightsmarketbeat.com
CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform. Total revenue rose to $132 million
Via MarketBeat · July 30, 2026
CareDx Announces Second Quarter 2026 Financial Results
CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026.
By CareDx, Inc. · Via Business Wire · July 30, 2026
What's going on in today's sessionchartmill.com
Via Chartmill · July 16, 2026
There are notable gap-ups and gap-downs in today's session.chartmill.com
Via Chartmill · July 16, 2026
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.
By CareDx, Inc. · Via Business Wire · July 16, 2026